This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

XTL Biopharmaceuticals Reports Full-Year 2011 Results

Stocks in this article: XTL XTLB

HERZLIYA, Israel, March 29, 2012 /PRNewswire/ --

XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY), a biopharmaceutical development company, today reported its results for the fourth quarter and year ended December 31, 2011.

David Grossman, CEO of XTL, stated, "2011 was a very significant year for XTL and we are very proud of our achievements in expanding our drug development pipeline with SAM-101 for the treatment of schizophrenia. SAM-101 is combination therapy of anti-psychotic existing drugs with minocycline. We now have a worldwide exclusive license for the development and commercialization of SAM-101 for the treatment of psychotic disorders. We in-licensed SAM-101 after it successfully completed a phase 2a prospective, randomized, double-blind, placebo-controlled clinical trial conducted on about 70 schizophrenics in Israel. The trial met its endpoints showing that SAM-101 improves the positive symptoms of the disease as well as the patients' cognitive state, minimizes the negative symptoms (social parameters and patient cognition) and reduces weight-gain side effects among patients".

"In the past year we were granted an orphan drug designation from the FDA for our rHuEPO for the treatment of multiple myeloma. The designation can provide us with significant regulatory and financial advantages to rapidly move our candidate forward in clinical trials. Upon the FDA's marketing approval for rHuEPO for the treatment of multiple myeloma we will be entitled to marketing exclusivity for seven years in the US. In addition, the benefits include among others tax incentives, exemption of FDA filing fees and clinical research financial subsidization". Mr. Grossman added, "Since the 4 th quarter of 2011, we are conducting a research which includes collection of data relating to the level of specific proteins in the blood of a group of patients with multiple myeloma with rHuEPO as part of the preparations for our phase 2 rHuEPO clinical trial."

"As of December 31, 2011 we had cash and cash equivalents of $1.5 million and in March 2012, we successfully completed a financing in Israel of approximately $3.8 million by way of private placement which also included an exercise of warrants, led by institutional investors. Such funds will enable us to finance our activities through at least into 2014 and support the acceleration of our drug development programs. Our strategy to continually identify and acquire new technologies remains and we are very keen in this front," stated Mr. Grossman.

"In March 2012, we also enhanced our capabilities of collecting clinical data by signing a strategic collaboration agreement with the research institute of Clalit Health Services, Israel's largest HMO. This agreement enables us to define clinical outcomes that we seek from Clalit's clinical database for the benefit of focusing our clinical trials design."

About XTL Biopharmaceuticals, Ltd

XTL Biopharmaceuticals, Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of clinical unmet needs. The Company is focused on late stage clinical development of drugs for the treatment of multiple myeloma, schizophrenia, and hepatitis C.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,397.11 +205.74 1.20%
S&P 500 2,013.60 +11.44 0.57%
NASDAQ 4,663.7490 +25.7550 0.56%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs